European Medicines Agency Accepts Extension Marketing Authorisation Application for Review of Celltrion's Remsima SC, the Subcutaneous Version of Remsima®
Celltrion, Inc. (KRX:068270) today announced that the European Medicines Agency (EMA) has accepted for review of the Extension Marketing Authorisation Application for ‘Remsima SC’, the subcutaneous (SC) version of Remsima®, the autoimmune disease therapeutic antibody biosimilar of infliximab. An opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) on the Extension Marketing Authorisation Application for Remsima SC is expected in the second half of 2019.
In a bid to secure competitiveness in the TNF-α inhibitor (autoimmune disease therapeutic agent) market through ‘twin-track’ strategy together with the existing intravenous (IV) formulation of Remsima®, Celltrion has developed Remsima SC, the SC version of infliximab. Since May 2016, Celltrion has conducted Phase 1 and Phase 3 clinical trials for the safety, pharmacokinetic and efficacy assessment of Remsima SC.
The development of subcutaneous formulation of Remsima® is one of Celltrion’s marketing strategies to increase TNF-α inhibitor market share. The subcutaneous formulation allows patients to conveniently inject it by themselves according to the administration cycle, unlike intravenous formulation of Remsima that requires patients to visit hospitals for the administration thereof.
Celltrion expects that the potential users will include patients who are satisfied with the therapeutic effects of infliximab and yet want to be administered with the subcutaneous formulation.
“Celltrion is set to promote its Remsima® and Remsima SC as global blockbusters by increasing the Remsima brand share in TNF-α inhibitor market under the strategy of diversifying products with existing IV formulation of Remsima®, already sharing 52% of the Europe’s original medicine market.” says an official from Celltrion. “In addition to these efforts, we will lead the TNF- α inhibitor market with upcoming commercialization of the SC formulation of ‘CT-P17’ as a high-concentration formulation of a proposed adalimumab biosimilar referencing AbbVie’s Humira®, which is undergoing clinical trials.”
About Celltrion, Inc.
Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacturing of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EC’s approval for Inflectra® and Remsima®, respectively, which is the world’s first mAb biosimilar to receive approval from a regulatory agency in a developed country. For more information, visit www.celltrion.com.
Josh Hwang, +82 32 850 5171 / Josh.email@example.com
Gunn Lee, +82 32 850 5168 / Gunhyuk.firstname.lastname@example.org
Heewon Park, +82 32 850 5356 / Heewon.email@example.com
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Mass Deployments of IoT Solutions Transforming China, Says GSMA27.6.2019 04:30:00 EEST | Tiedote
Chinese mobile operators are leading the world in the deployment of transformative Internet of Things (IoT) solutions, the GSMA announced today. By connecting the estimated 960 million1 devices via cellular networks, the country is realising the value of the IoT and transforming society through mass market deployments of smart home, smart industry and smart city solutions. According to GSMA Intelligence, China is the world’s largest IoT market with 64 per cent of the 1.5 billion global cellular connections including the rapidly growing Mobile IoT licensed LPWA technologies2. “Backed by proactive government support, China is now at the forefront in the development and mass deployment of innovative and transformative IoT based solutions based on Mobile IoT technology,” said Alex Sinclair, Chief Technology Officer, GSMA. “These new technologies are being implemented across multiple different vertical sectors fundamentally altering the way we live and work, delivering real-time information
Gemalto Instant Connect Signals New Era in Effortless Mobile Connectivity for Consumer eSIM-equipped Devices 27.6.2019 02:00:00 EEST | Tiedote
Thales announces the launch of Gemalto Instant Connect, a pioneering connectivity solution to simplify the connection of eSIM-enabled devices on a mobile network. While users are spared the inconvenience of establishing a Wi-Fi or Bluetooth connection to kick-start their mobile experience, OEMs and mobile operators can now provision devices with mobile connectivity at their first use, and not during manufacturing, saving both time and cost. Connected PCs and laptops will be the first devices to integrate this faster and more efficient approach to out-of-the-box connectivity for eSIMs. Going forwards, a wide array of OEMs and mobile operators stand to benefit from the solution, which is fully compliant with the latest GSMA Remote SIM Provisioning specifications. Between 2018 and 2022, an estimated 2.3 billion eSIM-compliant consumer devices will be shipped worldwide 1 . To date, eSIM-equipped devices have had to rely on some form of primary connectivity before they are able to activate
Quanterix Announces Agreement to Acquire UmanDiagnostics, World’s Leading Neurofilament Light (Nf-L) Antibody Supplier26.6.2019 23:00:00 EEST | Tiedote
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has entered into a definitive agreement to acquire privately held UmanDiagnostics AB for $22.5 million, comprised of $16 million in cash plus $6.5 million in Quanterix common stock. Uman is widely recognized to possess the leading antibodies available today to measure neurofilament light (Nf-L) and has become the provider of choice for biopharmaceutical and diagnostic applications. Uman, based in Umeå, Sweden, supplies Nf-L antibodies and ELISA kits, which are widely recognized by researchers and biopharmaceutical and diagnostics companies world-wide as the premier solution for the detection of Nf-L to advance the development of therapeutics and diagnostics for neurodegenerative conditions. Nf-L has seen a dramatic growth in the last three years since Quanterix developed the first assay using Uman’s antibodies that could relia
Elliott Statement on Bayer26.6.2019 19:44:00 EEST | Tiedote
Elliott Advisors (UK) Limited (“Elliott”), which advises funds that collectively hold shares of Bayer A.G. (“Bayer” or “the Company”) and economic equivalents with an aggregate value of €1.1 billion, acknowledges Bayer’s announcement to create a special litigation committee of the Supervisory Board (the “Special Committee”), and the retention of Mr. John Beisner of Skadden, Arps, Slate, Meagher & Flom LLP, as legal advisor to the Supervisory Board and Special Committee. Elliott welcomes these steps, and is confident that today’s statement marks a step change in Bayer’s approach to addressing the legal challenges currently facing the Company. Elliott believes that the creation of the Special Committee will provide a new level of oversight and a fresh perspective to a litigation strategy in need of a radical overhaul, and help guide the Company towards a rational, fair and swift settlement. The appointment of Mr. John Beisner not only provides Bayer with relevant litigation expertise, bu
Louisiana Launches Hepatitis C Innovative Payment Model With Asegua Therapeutics, Aiming to Eliminate the Disease26.6.2019 18:30:00 EEST | Tiedote
Today, Governor John Bel Edwards joined Secretary Rebekah Gee of the Louisiana Department of Health, Secretary James LeBlanc of the Louisiana Department of Corrections, and Asegua Therapeutics LLC, a wholly-owned subsidiary of Gilead Sciences, Inc. (Nasdaq: GILD), to announce a deal that will allow the implementation of an innovative payment model for hepatitis C treatment, part of Louisiana’s plan to eliminate the disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190626005539/en/ “This new model has the potential to save many lives and improve the health of our citizens. It is an important day for our state, for our partner Asegua Therapeutics, for providers, but most importantly for the patients and their families who will benefit from treatment,” said Governor Edwards. “Asegua was willing to come to the table to work with us to help Louisiana residents and we are pleased to initiate this five year partnership. Ultim
Nextflow Software Introduces Nextflow Studio, Its Newest Fluid Simulation Software26.6.2019 17:00:00 EEST | Tiedote
Nextflow Software is an Independent Software Vendor (ISV) based in Nantes, France. Nextflow Software is one of the leaders in innovative Computational Fluid Dynamics (CFD) methods. The startup exhibits at the NAFEMS World Congress in Quebec City, Canada, on June 17-20, featuring live demos if its latest product Nextflow Studio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190626005482/en/ Nextflow Studio conception simulation (Photo: Nextflow Software) A full environment covering all stages of CFD simulation Nextflow Studio is a software platform that covers the entire CFD flow, from pre-processing, to computation and post-processing. This environment lets engineers manage easily their simulation projects and provides a Graphical User Interface (GUI) based on the latest software technologies. Nextflow Studio offers an experience that allows users to accelerate the resolution of their field-specific design objectives. Main
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme